Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center (UMMC) now can receive long-term therapy based on information found in their genes. As part...
Elixir Medical Corp. announced it received CE (Conformité Européenne) mark approval for its DESolve Novolimus-eluting bioresorbable coronary stent scaffold system. The scaffold is...
University of Michigan researchers said the preliminary results of using biresorbable zinc stents were amazing, with corrosion rates exactly where they need to be for a stent successful platform...
For patients who received stents to restore blood flow through the main arteries supplying blood to the brain, inflating a tiny balloon inside the arteries after implantation of the stent ...
Cook Medical has initiated a global voluntary recall of its Zilver PTX Drug Eluting Peripheral Stent based on its investigation into a small number of complaints that the delivery system of the...
Stenting reopens completely blocked bowel arteries, preventing damage and even death from a condition that causes individuals severe pain and leads to excessive weight loss, notes research being...
Kidney failure patients on dialysis derive long-term benefit from the minimally invasive placement of a stent that improves the function of dialysis access grafts, according to 12-month clinical...
Cook Medical has launched the VIVO clinical research study to evaluate the safety and effectiveness of the Zilver Vena Venous Self-Expanding Stent in the treatment of...
The FREEDOM trial, the first long-term, comparative study of its kind exclusively for patients with diabetes and advanced multivessel coronary artery disease (CAD) revealed that diabetics with CAD...
Cardiologists at ACC.13 learned that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic Inc. as participants in one of several clinical studies and...
NeuroVive announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center clinical trial (CIRCUS trial) assessing CicloMulsion (a special formulation of...
March 26, 2013 — A multicenter analysis, led by Weill Cornell Medical College and published in the Journal of Clinical Gastroenterology, shows the use of temporary "fully covered...
Cordis Corp. announced it has completed the acquisition of Flexible Stenting Solutions Inc., whose technology provides Cordis with the opportunity to evolve the S.M.A.R.T. stent platform to...
Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) study at Middelheim...
Abbott announced positive long-term results for the company's innovative Absorb Bioresorbable Vascular Scaffold (BVS). Three-year results from 101 patients in the second stage of the ABSORB trial...
OrbusNeich announced that OrbusNeich Medical GmbH has commenced patent infringement actions in Germany and The Netherlands against Boston Scientific Corp. and its distribution affiliates in those...
The U.S. Food and Drug Administration (FDA) has approved the 34 and 38 mm lengths of the Medtronic Resolute Integrity drug-eluting stent in diameters of 3, 3.5 and 4 mm with an indication for...
Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES...
Coronary artery disease and peripheral artery disease are global health issues that affect millions of lives each year, and bioabsorbable stents are due to become the next step in treatment once...
The American College of Cardiology (ACC) has released the late-breaking clinical trials that will be highlighted as the cutting edge of cardiology at the ACC.13 annual meeting March 9-11 in San...
Biotronik announced the first U.S. implant of their Pulsar-18 self expanding stent in the BIOFLEX-I IDE clinical trial. Carlos Mena of Yale University Medical Center performed the procedure.
Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The randomized controlled trial will enroll about 2,250 patients and compare the performance of...
Biosensors International has announced enrollment of the first patient in LEADERS FREE, a clinical study involving BioFreedom, a polymer-free drug-coated stent (DCS) from Biosensors.
Abbott announced that the Xience Xpedition everolimus-eluting coronary stent system received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the...
When tests reveal that a patient’s heart artery is blocked and blood flow to the heart is restricted, should the doctor fix it with a stent or stop the test and discuss treatment options with the...
Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top...
December 27, 2012 — Biotronik announced that the first implant has taken place in the BIOHELIX-I trial in the United States. The BIOHELIX–I trial is set to evaluate the safety and...
December 26, 2012 — Flexible Stenting Solutions Inc. (FSS) announced it gained CE mark in the European Union for its 6 French Reconstrainable FlexStent Femoropopliteal self-expanding...
December 19, 2012 — The first patient has been enrolled in the Boston Scientific EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the Synergy ...
More than half of patients treated for claudication or critical limb ischemia (CLI) with stenting of the superficial femoral artery (SFA) had primary patency at five years, says a recent study.
Tryton Medical Inc. announced the completion of enrollment in the TRYTON Pivotal U.S. Food and Drug Administration (FDA) IDE trial evaluating the Tryton Side Branch...
Cordis Corp. announced that the U.S. Food and Drug Administration (FDA) has approved the S.M.A.R.T. Control Vascular Stent Systems for use in the superficial femoral artery (SFA) and/or the...
The U.S. Food and Drug Administration (FDA) granted market clearance for Cook Medical’s Zilver PTX drug-eluting peripheral stent. It is the first device of its kind on several fronts to go...
November 9, 2012 — Boston Scientific Corp. has received approval to update the directions for use (DFU) labeling for Promus Element and Promus Element Plus coronary drug eluting stent (DES)...
November 9, 2012 — Svelte Medical Systems announced it received conditional approval from the U.S. Food and Drug Administration (FDA) to begin a pivotal study for the Svelte coronary stent...
November 1, 2012 — InspireMD Inc. announced that its proprietary MGuard embolic protection stent (EPS) was shown to be significantly superior when compared to standard bare metal and drug-eluting...
Elixir Medical Corp. announced enrollment completion of the 120-patient, pivotal clinical trial evaluating the safety and efficacy of the DESolve Novolimus-Eluting...
October 23, 2012 — In the DEBATE-SFA trial, researchers found that the use of a paclitaxel drug-eluting balloon (DEB) to widen the artery prior to implanting a self-expanding nitinol stent yielded...
The Transcatheter Cardiovascular Therapeutics (TCT) conference showcases key advancements being made in interventional cardiology, focusing this year on the next generation of drug-eluting stents...
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced six-month clinical,...
Three-year data from the Zilver PTX randomized controlled trial of paclitaxel-eluting stents for femoropopliteal disease from Cook Medical demonstrate 70.7 percent primary patency in the...
Following Health Canada approval, Cook Medical has made the Zilver Vena Venous Self-Expanding Stent available to physicians across Canada. Designed to restore blood flow in obstructed iliofemoral...
The world’s first drug-eluting bioabsorbable vascular scaffold has been launched and will revolutionize the stent industry. On Sept. 25, 2012, Abbott announced the launch of its drug-eluting...
Boston Scientific has launched the Promus Element Plus BTK (Below The Knee) everolimus-eluting stent system in European countries for the treatment of certain severe peripheral artery lesions. The...
Abbott Vascular began its international launch of the Absorb coronary stent, the world's first drug-eluting bioresorbable vascular scaffold (BVS). It is now widely available across...
September 24, 2012 — Bio DG announced that its patent for a novel metal system, to use as biodegradable material in developing implantable medical devices, was granted by the U.S. Patent Office on...
September 18, 2012 — Inpatient hospital treatment accounts for the largest proportion of healthcare spending in the United States, with the use of diagnostic imaging services such as magnetic...
The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's...
August 22, 2012 — Authors of an article in the Journal of Endovascular Therapy have evaluated the effectiveness of endovascular brachytherapy using liquid beta-emitting rhenium-...
August 15, 2012 — Previously unreleased three-year data from the Zilver PTX randomized controlled trial of paclitaxel-eluting stents for femoropopliteal disease indicate that Cook Medical’s...
August 14, 2012 — The U.S. Food and Drug Administration (FDA) is hosting a public workshop that examines use of absorbable materials in implantable devices for endovascular therapies such as...
August 9, 2012 — The U.S. Food and Drug Administration (FDA) is informing healthcare providers and patients that the indications for use and labeling for the Stryker Wingspan...
Aug. 8, 2012 — The U.S. Food and Drug Administration (FDA) approved the Abbott’s Omnilink Elite Vascular Balloon-Expandable Stent System for the treatment of iliac artery disease. This...
As the average age of the U.S. population and the number of patients at high risk for cardiovascular disease increase, the usage of cardio and endovascular stents continues to grow. Interventional...
July 16, 2012 — Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting bioresorbable scaffold. A total of 26 patients have been enrolled and there are...
July 12, 2012 — Terumo Interventional Systems, a strategic business unit of Terumo Medical Corporation, a U.S. subsidiary of Terumo Corporation, announced the completion of U.S. patient enrollment...
July 3, 2012 — Flexible Stenting Solutions Inc., a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced that it has extended its CE...
June 21, 2012 — Plans for a new study involving BioFreedom, the polymer-free drug-coated stent (DCS) from Biosensors, were announced at EuroPCR by principal investigator Dr. Philip Urban,...
June 15, 2012 — Stentys SA, a medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced that it has...
Evaluating the performance of your cath lab is key to developing a strategic plan for improving service offerings, planning growth and expanding market share to compete for revenues. Availability...
June 4, 2012 — Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) regulatory approval of 32 mm and 38 mm lengths for the Promus Element Plus everolimus-eluting...
May 30, 2012 — Tryton Medical Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced results of a patient-level pooled analysis...
May 30, 2012 - According to study results to be featured in the late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual...
May 23, 2012 -- Boston Scientific Corp. announces U.S. Food and Drug Administration approval and market launch of the Epic Vascular Self-Expanding Stent System. The Epic Stent is designed to open...
May 23, 2012 — Boston Scientific Corp. announces that the Synergy everolimus-eluting bioabsorbable polymer-coated platinum chromium coronary stent demonstrated noninferior results in treating...
May 23, 2012 — Boston Scientific Corp. announced two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm Promus Element...
